INX-315
- CAS No.
- 2745060-92-6
- Chemical Name:
- INX-315
- Synonyms
- INX-315
- CBNumber:
- CB113837881
- Molecular Formula:
- C19H21N7O3S
- Molecular Weight:
- 427.48
- MDL Number:
- MOL File:
- 2745060-92-6.mol
INX-315 Chemical Properties,Uses,Production
Uses
INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research[1].
in vivo
INX-315 (100 mg/kg, p.o., twice daily for 56 days) effectively inhibits tumor growth in a gastric adenocarcinoma BALB/c nude mouse model[1]. INX-315 (100 mg/kg twice daily or 200 mg/kg once daily, i.p.) demonstrates significant tumor inhibition in the OVCAR3 ovarian cancer CDX model with good tolerance[2]. INX-315 (100 mg/kg twice daily, i.p.) demonstrates significant antitumor activity in the GA0103 gastric cancer PDX model with good tolerance[2].
| Animal Model: | OVCAR3 ovarian cancer CDX model constructed by injecting OVCAR3 ovarian cancer cell line into immunodeficient mice[2] |
| Dosage: | 100 or 200 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), 100 mg/kg twice daily or 200 mg/kg once daily for up to 42 days |
| Result: | Resulted in tumor stasis (100 mg/kg twice daily), achieved 89% tumor growth inhibition (TGI), and did not cause significant weight loss (200 mg/kg once daily). |
| Animal Model: | GA0103 gastric cancer PDX model constructed by injecting patient-derived GA0103 gastric cancer tumor into immunodeficient mice[2] |
| Dosage: | 100 mg/kg |
| Administration: | Intraperitoneal injection (i.p.), twice daily for 56 days |
| Result: | Resulted in tumor stasis and did not cause significant weight loss. |
| Animal Model: | CCNE1-amplified gastric adenocarcinoma PDX (GA0103) in BALB/c nude mice model[1] |
| Dosage: | 25, 50 或 100 mg/kg |
| Administration: | Oral gavage (p.o.), twice daily, for 56 days |
| Result: | inhibited the growth of tumor in a dose-dependent manner, with 100 mg/kg group showing tumor regression. |
References
[1] Dietrich C, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 2023 Dec 4. DOI:10.1158/2159-8290.CD-23-0954
[2] Trub A G, et al. INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers[J]. Cancer Research, 2023, 83(7_Supplement): 5994-5994.
INX-315 Preparation Products And Raw materials
Raw materials
Preparation Products
INX-315 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd | 15317229551 | 15151849396@163.com | China | 997 | 58 |
| Changzhou Borl Biotechnology Co.,LTD | 13606124132;13656121842 | luyan0021@163.com | China | 219 | 58 |
| Shanghai Tachizaki Biomedical Research Center | 18014399201 | sales@chemlab-tachizaki.com | China | 2672 | 58 |
| Nantong QuanYi Biotechnology Co., Ltd | 0513-66337626 18051384581 | sales@chemhifuture.com | China | 5519 | 58 |
| Jiangsu Aikon Biopharmaceutical R&D Co.,Ltd. | 025-66061636 18013972705 | qqyang@aikonchem.com | China | 10152 | 58 |
| Selleck Chemicals | 400-668-6834 | info@selleck.cn | China | 12071 | 58 |
| Suzhou Jinglige Technology Co., Ltd | 18551175068 | jinglige888@163.com | China | 232 | 58 |